Analysis of Plasma Metabolic Profile Characteristics in Gouty Arthritis With Dampness Syndrome
Abstract
Objective
To investigate the metabolic characteristics of gouty arthritis (GA) with dampness syndrome (GA-DS), to identify potential diagnostic and recurrence-predictive biomarkers, and to preliminarily elucidate the underlying mechanisms of the effect of traditional Chinese medicine (TCM) dampness syndrome on metabolic abnormalities in patients with gout.
Methods
The study was conducted as part of a clinical trial—Clinical Cohort Construction and Efficacy Evaluation of Gouty Arthritis With Dampness Syndrome, which has been registered in the Chinese Clinical Trial Registry (ChiCTR) and assigned the registration number of ChiCTR2000038969. Healthy controls (HC), patients with GA-DS, and those with GA with non-dampness syndrome (GA-NDS) were enrolled. Clinical assessments of metabolic and inflammatory parameters were performed, and targeted metabolomic profiling of plasma samples was conducted. Diagnostic and recurrence prediction models were constructed using random forest and logistic regression, and the efficacy of the recurrence model was validated in an independent cohort.
Results
GA-DS patients exhibited significant metabolic disturbances, with significantly elevated levels of body mass index (BMI), serum uric acid (SUA), and lipid metabolism indicators. Metabolomic analysis revealed significantly elevated plasma acetovanillone and cyclic adenosine monophosphate (cAMP) in the GA-DS group compared with those in the HC and GA-NDS groups (all q < 0.05). These two metabolites were significantly correlated with SUA and the inflammatory marker C-reactive protein levels (r = 0.50 and r = 0.48, respectively; both P < 0.05). A logistic regression model based on acetovanillone and cAMP effectively distinguished GA-DS patients from HC and GA-NDS patients (out-of-bag error: 0.158 ± 0.038; accuracy: [84.2 ± 6.6]%; adjusted P < 0.001 for both indicators vs. those of the other models). Further analysis showed that cAMP and ureidosuccinic acid levels increased in patients who later experienced GA recurrence (P < 0.05), with detectable changes as early as 24 weeks before recurrence. A recurrence prediction model combining cAMP and creatine kinase-MB (CK-MB) achieved the best performance and was validated in an independent cohort (accuracy: 67.39%, 95% CI: 52.0%-80.5%; area under the curve [AUC] = 0.803, 95% CI: 0.676-0.930).
Conclusion
GA-DS patients display distinct metabolic abnormalities. Acetovanillone and cAMP hold promise as diagnostic biomarkers, while cAMP in combination with CK-MB can be used for the early prediction of the risk of GA-DS recurrence. These findings provide novel insights into the metabolic basis of TCM dampness syndrome and offer potential biomarkers for early diagnosis and stratification of recurrence risk in GA.
Keywords: Gouty arthritis, Dampness syndrome, Recurrence, Cyclic AMP, Ureidosuccinic acid
Full Text:
PDFReferences
DALBETH N, GOSLING A L, GAFFO A, et al. Gout. Lancet, 2021, 397(10287): 1843-1855. doi: 10.1016/S0140-6736(21)00569-9.
XIA Y, WU Q, WANG H, et al. Global, regional and national burden of gout, 1990-2017: a systematic analysis of the Global Burden of Disease Study. Rheumatology (Oxford), 2020, 59(7): 1529-1538. doi: 10.1093/rheumatology/kez476.
PAN Z, HUANG M K, FANG M, et al. Socioeconomic differences in hyperuricemia and gout: a systematic review and meta-analysis. Endocrine, 2020, 69(2): 286-293. doi: 10.1007/s12020-020-02281-w. EUN Y,
HAN K, LEE S W, et al. Altered risk of incident gout according to changes in metabolic syndrome status: a nationwide, population-based cohort study of 1.29 million young men. Arthritis Rheumatol, 2023, 75(5): 806-815. doi:10.1002/art.42381.
KOTO R, NAKAJIMA A, HORIUCHI H, et al. Serum uric acid control for prevention of gout flare in patients with asymptomatic hyperuricaemia: a retrospective cohort study of health insurance claims and medical check-up data in Japan. Ann Rheum Dis, 2021, 80(11): 1483-1490. doi: 10.1136/annrheumdis-2021-220439.
DEHLIN M, JACOBSSON L, RODDY E. Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors. Nat Rev Rheumatol, 2020, 16(7): 380-390. doi: 10.1038/s41584-020-0441-1.
SHEN J C, WANG H B, LIU Y Q. Research progress of traditional Chinese medicine in the treatment of gouty arthritis. Journal of Clinical Medicine in Practice, 2023, 27(12): 129. doi: 10.7619/jcmp.20231061.
WANG W T, FENG J H, YANG K, et al. Pharmacodynamic substances and mechanism of action of Huanglian Jiedu Decoction in the treatment of gouty arthritis: a study based on UPLC-Q-TOF/ MS, network pharmacology, and molecular docking simulation. Journal of Chongqing Medical University, 2025, 50(7): 860-869. doi: 10.13406/j.cnki.cyxb. 003855.
NEOGI T, JANSEN T L, DALBETH N, et al. 2015 gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis, 2015, 74(10): 1789-1798. doi: 10.1136/annrheumdis-2015-208237.
LI Q, YANG X B. Interpretation on diagnostic attributes and diagnostic modes of Chinese medicine syndrome: as illustrated by the case of Dampness syndrome. Modernization of Traditional Chinese Medicine and Materia Medica-World Science and Technology, 2023, 25(6): 2230-2236. doi: 10.11842/wst.20220513011.
QASEEM A, MCLEAN R M, STARKEY M, et al. Diagnosis of acute gout: a clinical practice guideline from the American College of Physicians. Ann Intern Med, 2017, 166(1): 52-57. doi: 10.7326/M16-0569.
QASEEM A, HARRIS R P, FORCIEA M A, et al. Management of acute and recurrent gout: a clinical practice guideline from the American College of Physicians. Ann Intern Med, 2017, 166(1): 58-68. doi: 10.7326/M16-0570.
ABD El-GHAFAR O A M, HASSANEIN E H M, ALI F E M, et al. Hepatoprotective effect of acetovanillone against methotrexate hepatotoxicity: role of Keap-1/Nrf2/ARE, IL6/STAT-3, and NF-kappaB/AP-1 signaling pathways. Phytother Res, 2022, 36(1): 488-505. doi: 10.1002/ptr.7355.
ABD El-GHAFAR O A M, HASSANEIN E H M, SAYED A M, et al. Acetovanillone prevents cyclophosphamide-induced acute lung injury by modulating PI3K/Akt/mTOR and Nrf2 signaling in rats. Phytother Res, 2021, 35(8): 4499-4510. doi: 10.1002/ptr.7153.
PANDEY A, KOUR K, BANI S, et al. Amelioration of adjuvant induced arthritis by apocynin. Phytother Res, 2009, 23(10): 1462-1468. doi: 10. 1002/ptr.2803.
AMAN R M, ZAGHLOUL R A, ELSAED W M, et al. In vitro-in vivo assessments of apocynin-hybrid nanoparticle-based gel as an effective nanophytomedicine for treatment of rheumatoid arthritis. Drug Deliv Transl Res, 2023, 13(11): 2903-2929. doi: 10.1007/s13346-023-01360-5.
LAFEBER F P, BEUKELMAN C J, Van den WORM E, et al. A plant-derived, cartilage-saving drug, might be useful in the treatment of rheumatoid arthritis. Rheumatology (Oxford), 1999, 38(11): 1088-1093. doi: 10.1093/rheumatology/38.11.1088.
RAYEES S, JOSHI J C, TAUSEEF M, et al. PAR2-mediated cAMP generation suppresses TRPV4-dependent Ca(2+) signaling in alveolar macrophages to resolve TLR4-induced inflammation. Cell Rep, 2019, 27(3): 793-805 e4. doi: 10.1016/j.celrep.2019.03.053.
ZHU N, CUI J, QIAO C, et al. cAMP modulates macrophage development by suppressing M-CSF-induced MAPKs activation. Cell Mol Immunol, 2008, 5(2): 153-157. doi: 10.1038/cmi.2008.19.
FENNELL E M J, APONTE-COLLAZO L J, PATHMASIRI W, et al. Multi-omics analyses reveal ClpP activators disrupt essential mitochondrial pathways in triple-negative breast cancer. Front Pharmacol, 2023, 14: 1136317. doi: 10.3389/fphar.2023.1136317.
LI B, SHU X, JIANG H, et al. Plasma metabolome identifies potential biomarkers of gastric precancerous lesions and gastric cancer risk. Metabolomics, 2023, 19(8): 73. doi: 10.1007/s11306-023-02037-3.
Refbacks
- There are currently no refbacks.
